Zentalis Pharmaceuticals, Inc. Soared

Zentalis Pharmaceuticals, Inc. (ZNTL:NASDAQ) shot up at $3.74, a gain of 31.7%. On Fri, Jan 09, 2026, ZNTL:NASDAQ touched a New 2-Week High of $3.74. The stock appeared on our News Catalysts scanner on Thu, Jan 08, 2026 at 02:58 AM in the 'MISCELLANEOUS' category. From Fri, Dec 26, 2025, the stock recorded 66.67% Up Days and 60.00% Green Days

About Zentalis Pharmaceuticals, Inc. (ZNTL:NASDAQ)

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company's product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. Its other products include ZN-c3, ZN-d5, and ZN-e4.